TRAUMA
Menatetrenone, risedronate and calcium prevent fractures in Alzheimer’s patients
This report has been verified
by one or more authors of the
original publication.
Kurume Med J. 2011;57(4):117-24
231 patients suffering from Alzheimer's disease were recruited to participate in this study to determine the preventative effects of menatetrenone, risedronate and calcium on hip fractures, over one year. All patients were administered 17.5 mg risedronate and 1200mg calcium weekly; patients were then randomized to receive 45mg menatrenone daily or a placebo. The results suggested that menatetrenone, risedronate and calcium were a safe combination of medications that prevented fractures and increased bone mineral density in elderly patients with Alzheimer’s.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
